Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Ultimately a marker of microglial activation could be used for large-scale quantitative brain
imaging trials in Alzheimer Disease (AD), Parkinson Disease (PD) or Multiple Sclerosis (MS),
specifically to investigate the agent as an objective biomarker in treatments aimed at
reducing inflammatory changes in these conditions. The significance of this work lies in
applying state-of-art quantitative neuroimaging tools to develop a relevant biomarker in
individuals with neurodegenerative diseases with the intention of using this efficiently in
large clinical imaging trials.